Atorvastatin administration is associated with dose-related changes in IGF bioavailability

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 543-548

  Narayanan, Ram P ^a   Gittins, Matthew ^a   Siddals, Kirk W ^a   Oliver, Robert L ^a   Hudson, Julie E ^a   White, Anne ^a   Durrington, Paul ^a   Davies, Robert R ^b   Rutter, Martin K ^a,b   Gibson, J Martin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIABETOGENESIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; GLUCOSE TOLERANCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; PYRROLES;

EID: 84875182002     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0844     Document Type: Article

References (28)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R et al. Efficacy and safety of cholesterol-lowering treatment: prospectivemeta-analysis of data from 90,056participants in14randomised trials of statins. Lancet2005366 1267-1278. (doi:10.1016/S0140-6736(05)67394-1)
2. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS et al. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis. Journal of the American Medical Association 2011 305 2556-2564. (doi:10.1001/jama.2011.860)
3. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34. (doi:10.1210/edrv-16-1-3)
4. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB & Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745. (doi:10.1016/S0140-6736(02)08655-5)
5. Wallander M, BrismarK,Ohrvik J,Ryden L&NorhammarA. Insulinlike growth factor I: a predictor of long-termglucose abnormalities in patients with acute myocardial infarction. Diabetologia 2006 49 2247-2255. (doi:10.1007/s00125-006- 0386-1)
6. Teppala S & Shankar A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care 2010 33 2257-2259. (doi:10.2337/dc10-0770)
7. Schneider HJ, Friedrich N, Klotsche J, Schipf S, Nauck M, Valzke H, Sievers C, Pieper L,MorzW,WittchenH-U et al. Prediction of incident diabetes mellitus by baseline IGF1 levels. European Journal of Endocrinology 2011 164 223-229. (doi:10.1530/EJE-10-0963)
8. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 2010 42 105-116. (doi:10.1038/ng.520)
9. Hill D, Livingstone K, Thomson JE, Perry C & Wark G. IGF-II secreting solitary fibrous tumour of the liver presenting with hypoglycaemia. Scottish Medical Journal 2008 53 60-61. (doi:10.1258/rsmsmj.53.1.60c)
10. Petersson U, Ostgren CJ, Brudin L, Brismar K & Nilsson PM. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes & Metabolism 2009 35 198-205. (doi:10.1016/j.diabet.2008.11.003)
11. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K & Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type2diabetes inmiddle-agedSwedishmen. Diabetologia 2008 51 1135-1145. (doi:10.1007/s00125-008-1016-x)
12. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, TaylorW, FraserW,White A et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001 44 333-339. (doi:10.1007/s001250051623)
13. Siddals KW, Marshman E, Westwood M & Gibson JM. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. Journal of Biological Chemistry 2004 279 38353-38359. (doi:10.1074/jbc.M404838200)
14. Rutter MK, Prais HR, Charlton Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG et al. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabetic Medicine 2011 28 100-108. (doi:10.1111/j.1464-5491.2010.03139.x)
15. Crosby SR, Anderton CD, Westwood M, Holly JM, Cwyfan Hughes SC, Gibson M, Morrison CA, Young RJ & White A. Measurement of insulin-like growth factor-II in human plasma using a specific monoclonal antibody-based two-site immunoradiometric assay. Journal of Endocrinology 1993 137 141-150. (doi:10.1677/joe.0.1370141)
16. Froesch ER & Zapf J. Insulin-like growth factors and insulin: comparative aspects. Diabetologia 1985 28 485-493. (doi:10.1007/BF00281982)
17. Zapf J, Hauri C,Waldvogel M & Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. Journal of Clinical Investigation 1986 77 1768-1775. (doi:10.1172/JCI112500)
18. Conover CA & Lee PD. Insulin regulation of insulin-like growth factor-binding protein production in cultured HepG2 cells. Journal of Clinical Endocrinology and Metabolism 1990 70 1062-1067. (doi:10.1210/jcem-70-4-1062)
19. Weaver JU, Holly JM, Kopelman PG, Noonan K, Giadom CG, White N, Virdee S & Wass JA. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clinical Endocrinology 1990 33 415-422. (doi:10.1111/j.1365-2265.1990.tb00507.x)
20. Kotronen A, Lewitt M, Hall K, Brismar K & Yki-Jarvinen H. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2008 93 4867-4872. (doi:10.1210/jc.2008-1245)
21. Lewitt MS, Hilding A, Brismar K, Efendic S, Ostenson C-G & Hall K. IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. European Journal of Endocrinology 2010 163 233-242. (doi:10.1530/EJE-10-0301)
22. Qiu C, Vadachkoria S, Meryman L, Frederick IO & Williams MA. Maternal plasma concentrations of IGF-1, IGFBP-1, and C-peptide in early pregnancy and subsequent risk of gestational diabetes mellitus. American Journal of Obstetrics and Gynecology 2005 193 1691-1697. (doi:10.1016/j.ajog.2005.04.015)
23. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW et al. Statins and risk of incident diabetes: a collaborative metaanalysis of randomised statin trials. Lancet 2010 375 735-742. (doi:10.1016/S0140-6736(09)61965-6)
24. Betteridge DJ & Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine 2007 24 541-549. (doi:10.1111/j.1464-5491.2007.02095.x)
25. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ & Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. Journal of the American College of Cardiology 2010 55 1209-1216. (doi:10.1016/j.jacc.2009.10.053)
26. Szkodzinski J, Romanowski W, Hudzik B, Kaszuba A, Nowakowska-Zajdel E, Szkilnik R, Pietrasinska B & Zubelewicz-Szkodzinska B. Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients. Pharmacological Reports: PR 2009 61 654-664.
27. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A & Gibson JM. Low circulating levels of insulinlike growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002 51 2629-2636. (doi:10.2337/diabetes.51.8.2629)
28. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L & Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007 30 2343-2348. (doi:10.2337/dc07-0825)